21st Annual Psychopharmacology Update

Friday, October 28, 2022, 9:00 AM - Saturday, October 29, 2022, 5:30 PM, The Westin Cincinnati, 21 E. 5th St., Cincinnati, OH

AMA PRA Category 1 Credits™ (13.50 hours), AMA PRA Category 1 Credits™ Designated (13.50 hours)

The 21st Annual Psychopharmacology Update will be presented as a 2-day live in-person and virtual hybrid conference October 28-29, 2022, providing a blended learning curriculum comprised of deep-dive workshops and advanced educational sessions with interactive audience Q&A and polling. Conference sessions will be live-streamed during the event and available on-demand 24/7 through December 31, 2022, to extend the accessibility of this valuable educational content. 

The program features 3 CME-certified preconference workshops: Addiction Management, Medical Cannabis, and Telepsychiatry. Nationally renowned faculty will present the Masterclass providing expert guidance and clinical updates on managing treatment resistance in psychiatric syndromes, addressing a perennial challenge in the psychiatric community.

Format: CME/CE Live In-person + Virtual Hybrid Conference
Dates: October 28, 2022 (Workshops), October 29, 2021 (Masterclass), On-demand  through December 31, 2022
Credits: Up to 13.5 AMA PRA Category 1 Credits™., ANCC contact hours, ABPN MOC
Faculty: 12 clinician faculty.

For more information and to register, visit: Psychpharm Update website.

Registration Fee ranges from 
$50.00 to $345.00 depending on date and profession

1. Discuss current definitions, criteria, and recent guidelines for treatment resistance in various psychiatric disorders
2. Distinguish between pseudo-resistance, primary and secondary treatment resistance
3. Identify evidence-based strategies to accurately assess treatment resistance among diverse patients with psychiatric disorders and those with comorbidities
4. Evaluate current and novel pharmacological treatment options for treatment-resistant psychiatric disorders, including combination therapies
5. Review available and emerging non-pharmacologic treatment options for treatment-resistant psychiatric disorders

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Global Academy for Medical Education.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this live activity for a maximum of 13.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees' professional development.

The Westin Cincinnati
21 E 5th Street
Cincinnati, OH  45202
(513) 621-7700

Mitigation of Relevant Financial Relationships

The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24-months. All relevant relationships have been mitigated prior to the commencement of the activity.

Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.

No faculty are available for this activity at this time.